Neurolixis is a biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) disorders, focusing on conditions with significant unmet medical needs. The company is advancing several promising compounds, including NLX-112, NLX-101, and NLX-204. NLX-112 is currently in Phase 2 clinical trials for movement disorders, particularly dyskinesia associated with Parkinson's disease, demonstrating strong efficacy in animal models. NLX-101, which targets Rett syndrome and other autism spectrum disorders, is notable for its unique mechanism as a biased agonist at serotonin 5-HT1A receptors, showing potential for both antidepressant effects and cognitive enhancement after a single dose. NLX-204 is in preclinical development for depression and pain management.

The research and development efforts at Neurolixis are supported by various non-dilutive funding sources, including grants from prominent foundations such as the Michael J. Fox Foundation and Parkinson's UK. The company’s focus on rare and challenging CNS disorders, such as Rett syndrome and Fragile X syndrome, highlights its commitment to addressing critical gaps in treatment options. Neurolixis has received recognition for its innovative approaches, including winning the Occitanie Silver Trophées for its advancements in drug development, particularly for NLX-112. This recognition underscores the company's potential impact on the treatment landscape for neurodegenerative and psychiatric conditions.

United States

Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including movement disorders, autism spectrum disorders, depression and pain.

Neurolixis

Company Details